Metabolic modulator comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
In 2002, the Nobel Prize in Chemistry was awarded to John Bennett Fenn for the development of electrospray ionization (ESI) and Koichi Tanaka for the development of soft laser desorption and their application to the ionization of biological macromolecules, especially proteins.
=== Distribution, phenology, and ecology === Fungarium records provide a historical record of global biodiversity that can be linked to environmental change. Georeferenced metadata allow researchers to connect specimens to historical climate and land-use databases such as WorldClim. Analysis of collection dates in Europe has revealed delays in the autumnal fruiting season and a general widening of the season for saprotrophic fungi. Specimens have also been used to trace invasive species; for example, the introduction and spread of Amanita phalloides in the western United States was reconstructed using DNA from collections spanning a century. Stable carbon and nitrogen isotope analysis of sporocarps in the genus Ramaria has confirmed their nutritional modes and roles in carbon cycling. Although many historical records lack geographic coordinates or contain only vague locality descriptions, retrospective georeferencing can make older specimens more useful for spatial analyses such as species distribution modelling, provided the associated uncertainty is documented.
=== DES litigation === Lilly was one of numerous manufacturers of diethylstilbestrol (DES), a synthetic estrogen that was prescribed to pregnant women to prevent pregnancy complications such as miscarriage. In 1971, researchers linked prenatal DES exposure to clear-cell adenocarcinoma of the vagina and cervix. The Food and Drug Administration responded by advising physicians not to prescribe DES to pregnant women. More than 300 companies manufactured DES, which later complicated litigation because plaintiffs often could not identify which manufacturer had supplied the drug taken by their mothers. In Bichler v. Eli Lilly and Company, Joyce Bichler sued Lilly after developing cervical and vaginal cancer at age 17 following prenatal exposure to DES. In 1982, the New York Court of Appeals upheld a $500,000 jury award to Bichler even though it had not been established that Lilly manufactured the particular DES taken by her mother. In the 1989 case Hymowitz v. Eli Lilly and Company, the New York Court of Appeals adopted a form of market share liability for DES cases that allowed liability to be apportioned among manufacturers according to their share of the national DES market when the specific producer could not be identified. DES litigation continued for decades. In 2013, Lilly reached an undisclosed settlement during a federal trial brought by four sisters who alleged that their breast cancers resulted from DES their mother had taken during pregnancy. Lilly disputed that DES caused their cancers and disputed whether their mother had taken DES manufactured by Lilly.
Sources: en.wikipedia.org
This use is of particular interest for being nontoxic and sustainable compared to other materials in moringa-growing regions where drinking water is affected by pollutants. In 2026, it was also reported that the plant's seed-based saline extract was able to remove 98% of microplastics from tap water. Moringa oleifera thus showed its potential as a sustainable alternative for microplastics removal from drinking water via in-line filtration.
Ion exchangers can have binding preferences for certain ions or classes of ions, depending on the physical properties and chemical structure of both the ion exchanger and ion. This can be dependent on the size, charge, or structure of the ions. Common examples of ions that can bind to ion exchangers are:
A eukaryotic initiation factor eIF3 plays an important role in translational initiation. It has a complex structure, composed of 13 subunits. It helps to create the 43S pre-initiation complex, composed of the small 40S subunit attached to other initiation factors. It also helps to create the 48S pre-initiation complex, consisting of the 43S complex with the mRNA. The eIF3 factor can also be used post-translation in order to separate the ribosomal complex and keep the small and large subunits apart. The initiation factor interacts with the eIF1 and eIF5 factors used for scanning and selection of the start codons. This can create changes in the selection of the factors, binding to different codons. Another important eukaryotic initiation factor, eIF2, binds the tRNA containing methionine to the P site of the small ribosome. The P site is where the tRNA carrying an amino acid forms a peptide bond with the incoming amino acids and carries the peptide chain. The factor consists of an alpha, beta, and gamma subunit. The eIF2 gamma subunit is characterized by a GTP-binding domain and beta-barrel folds. It binds to the tRNA through GTP. Once the initiation factor helps the tRNA bind, the GTP hydrolyzes and is released the eIF2. The eIF2 beta subunit is identified by its Zn-finger. The eIF2 alpha subunit is characterized by an OB-fold domain and two beta strands. This subunit helps to regulate translation, as it becomes phosphorylated to inhibit protein synthesis.
=== Common resins === DEAE-C is commonly commercially available as DE52 and DE53. These resins are prepared preswollen although cellulose exchangers swell in a strong basic environment to increase access to binding sites. DE52 has a pKa of 11.5. The buffering range for diethanolamine is 8.4-8.8, though the range for DEAE-C varies between manufacturers.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.